Clinical Characteristics, Prognosis Factors and Metagenomic Next-Generation Sequencing Diagnosis of Mucormycosis in Patients With Hematologic Diseases

Overview

Journal Mycopathologia

Specialties Microbiology
Pharmacology

Date 2024 Aug 1

PMID 39088077

Authors

Jieru Wang

Li Liu

Jia Li

Xiaomeng Feng

Huiming Yi

Erlie Jiang

Yizhou Zheng

Fengkui Zhang

Xiaofan Zhu

Yingchang Mi

Mingzhe Han

Jianxiang Wang

Sizhou Feng

Affiliations

Soon will be listed here.

Abstract

Introduction: New diagnostic methods and antifungal strategies may improve prognosis of mucormycosis. We describe the diagnostic value of metagenomic next⁃generation sequencing (mNGS) and identify the prognostic factors of mucormycosis.

Methods: We conducted a retrospective study of hematologic patients suffered from mucormycosis and treated with monotherapy [amphotericin B (AmB) or posaconazole] or combination therapy (AmB and posaconazole). The primary outcome was 84-day all-cause mortality after diagnosis.

Results: Ninety-five patients were included, with "proven" (n = 27), "probable" (n = 16) mucormycosis confirmed by traditional diagnostic methods, and "possible" (n = 52) mucormycosis with positive mNGS results. The mortality rate at 84 days was 44.2%. Possible + mNGS patients and probable patients had similar diagnosis processes, overall survival rates (44.2% vs 50.0%, p = 0.685) and overall response rates to effective drugs (44.0% vs 37.5%, p = 0.647). Furthermore, the median diagnostic time was shorter in possible + mNGS patients than proven and probable patients (14 vs 26 days, p < 0.001). Combination therapy was associated with better survival compared to monotherapy at six weeks after treatment (78.8% vs 53.1%, p = 0.0075). Multivariate analysis showed that combination therapy was the protective factor (HR = 0.338, 95% CI: 0.162-0.703, p = 0.004), though diabetes (HR = 3.864, 95% CI: 1.897-7.874, p < 0.001) and hypoxemia (HR = 3.536, 95% CI: 1.874-6.673, p < 0.001) were risk factors for mortality.

Conclusions: Mucormycosis is a life-threatening infection. Early management of diabetes and hypoxemia may improve the prognosis. Exploring effective diagnostic and treatment methods is important, and combination antifungal therapy seems to hold potential benefits.

References

Kontoyiannis D, Marr K, Park B, Alexander B, Anaissie E, Walsh T . Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010; 50(8):1091-100. DOI: 10.1086/651263. View

Jeong W, Keighley C, Wolfe R, Lee W, Slavin M, Kong D . The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2018; 25(1):26-34. DOI: 10.1016/j.cmi.2018.07.011. View

Choksi T, Agrawal A, Date P, Rathod D, Gharat A, Ingole A . Cumulative Mortality and Factors Associated With Outcomes of Mucormycosis After COVID-19 at a Multispecialty Tertiary Care Center in India. JAMA Ophthalmol. 2021; 140(1):66-72. PMC: 8662533. DOI: 10.1001/jamaophthalmol.2021.5201. View

Katragkou A, Walsh T, Roilides E . Why is mucormycosis more difficult to cure than more common mycoses?. Clin Microbiol Infect. 2013; 20 Suppl 6:74-81. DOI: 10.1111/1469-0691.12466. View

Gu W, Miller S, Chiu C . Clinical Metagenomic Next-Generation Sequencing for Pathogen Detection. Annu Rev Pathol. 2018; 14:319-338. PMC: 6345613. DOI: 10.1146/annurev-pathmechdis-012418-012751. View

Cornely O, Alastruey-Izquierdo A, Arenz D, Chen S, Dannaoui E, Hochhegger B . Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019; 19(12):e405-e421. PMC: 8559573. DOI: 10.1016/S1473-3099(19)30312-3. View

Muthu V, Agarwal R, Dhooria S, Sehgal I, Prasad K, Aggarwal A . Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis. Clin Microbiol Infect. 2021; 27(4):538-549. DOI: 10.1016/j.cmi.2020.12.035. View

Donnelly J, Chen S, Kauffman C, Steinbach W, Baddley J, Verweij P . Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019; 71(6):1367-1376. PMC: 7486838. DOI: 10.1093/cid/ciz1008. View

Segal B, Herbrecht R, Stevens D, Ostrosky-Zeichner L, Sobel J, Viscoli C . Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008; 47(5):674-83. PMC: 2671230. DOI: 10.1086/590566. View

10.

Chiu C, Miller S . Clinical metagenomics. Nat Rev Genet. 2019; 20(6):341-355. PMC: 6858796. DOI: 10.1038/s41576-019-0113-7. View

11.

Wang M, Zhang H, He Y, Qin C, Liu X, Liu M . Association Between Ischemic Stroke and COVID-19 in China: A Population-Based Retrospective Study. Front Med (Lausanne). 2022; 8:792487. PMC: 8898959. DOI: 10.3389/fmed.2021.792487. View

12.

Hu Y, Hu Q, Wei R, Li R, Zhao D, Ge M . The XRE Family Transcriptional Regulator SrtR in Is Involved in Oxidant Tolerance and Virulence. Front Cell Infect Microbiol. 2019; 8:452. PMC: 6335249. DOI: 10.3389/fcimb.2018.00452. View

13.

Xu C, Chen X, Zhu G, Yi H, Chen S, Yu Y . Utility of plasma cell-free DNA next-generation sequencing for diagnosis of infectious diseases in patients with hematological disorders. J Infect. 2022; 86(1):14-23. DOI: 10.1016/j.jinf.2022.11.020. View

14.

Bretagne S, Sitbon K, Desnos-Ollivier M, Garcia-Hermoso D, Letscher-Bru V, Cassaing S . Active Surveillance Program to Increase Awareness on Invasive Fungal Diseases: the French RESSIF Network (2012 to 2018). mBio. 2022; 13(3):e0092022. PMC: 9239099. DOI: 10.1128/mbio.00920-22. View

15.

Patel A, Kaur H, Xess I, Michael J, Savio J, Rudramurthy S . A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2019; 26(7):944.e9-944.e15. DOI: 10.1016/j.cmi.2019.11.021. View

16.

Kyvernitakis A, Torres H, Jiang Y, Chamilos G, Lewis R, Kontoyiannis D . Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016; 22(9):811.e1-811.e8. DOI: 10.1016/j.cmi.2016.03.029. View

17.

Nam B, Kim T, Lee K, Kim T, Han J, Chung M . Pulmonary mucormycosis: serial morphologic changes on computed tomography correlate with clinical and pathologic findings. Eur Radiol. 2017; 28(2):788-795. DOI: 10.1007/s00330-017-5007-5. View

18.

Alexander B, Lamoth F, Heussel C, Prokop C, Desai S, Morrissey C . Guidance on Imaging for Invasive Pulmonary Aspergillosis and Mucormycosis: From the Imaging Working Group for the Revision and Update of the Consensus Definitions of Fungal Disease from the EORTC/MSGERC. Clin Infect Dis. 2021; 72(Suppl 2):S79-S88. DOI: 10.1093/cid/ciaa1855. View

19.

Chatterjee N, Jensen P, Harris A, Nguyen D, Huang H, Cheng R . Admission respiratory status predicts mortality in COVID-19. Influenza Other Respir Viruses. 2021; 15(5):569-572. PMC: 8242415. DOI: 10.1111/irv.12869. View

20.

Singh A, Singh R, Joshi S, Misra A . Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021; 15(4):102146. PMC: 8137376. DOI: 10.1016/j.dsx.2021.05.019. View